Dual inhibitory action of a novel akr1c3 inhibitor on both full-length ar and the variant AR-V7 in enzalutamide resistant metastatic castration resistant prostate cancer
10.3390/cancers12082092
Saved in:
Main Authors: | Kafka, M., Mayr, F., Temml, V., Möller, G., Adamski, J., Höfer, J., Schwaiger, S., Heidegger, I., Matuszczak, B., Schuster, D., Klocker, H., Bektic, J., Stuppner, H., Eder, I.E. |
---|---|
Other Authors: | BIOCHEMISTRY |
Format: | Article |
Published: |
MDPI AG
2021
|
Subjects: | |
Online Access: | https://scholarbank.nus.edu.sg/handle/10635/199759 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Institution: | National University of Singapore |
Similar Items
-
Hormonal therapeutics enzalutamide and abiraterone acetate in the treatment of metastatic castration-resistant prostate cancer (mCRPC) post-docetaxel-an indirect comparison
by: Tan, P.S., et al.
Published: (2016) -
Extracellular Citrate Fuels Cancer Cell Metabolism and Growth
by: Haferkamp, S., et al.
Published: (2021) -
NFIC REGULATES AR MEDIATED TRANSCRIPTION BY MULTIPLE MECHANISMS
by: YANG CHONG
Published: (2013) -
Antarlides: A New Type of Androgen Receptor (AR) Antagonist that Overcomes Resistance to AR-Targeted Therapy
by: Shun Saito, et al.
Published: (2018) -
Post hoc analyses of East Asian patients from the randomized placebo-controlled PREVAIL trial of enzalutamide in patients with chemotherapy-naïve, metastatic castration-resistant prostate cancer
by: Kim C.S., et al.
Published: (2018)